Hytinon 500mg Korea United Treatment Treatment of chronic leukemia (10 blisters x 10 tablets)
Dosage form Box of 10 blisters x 10 tablets
Specifications Hydroxyurea
Ingredient
| Composition information | Content |
| Hydroxyurea | 500mg |
Uses
indications
Hytinon 500mg drug is indicated in the following cases:
Hydroxyurea inhibits specific in phase S of the cell cycle, stopping the progression of the border between the G1 phase and the S phase should inhibit the synthesis of DNA.Hydroxyurea's cytotoxic effect is limited to tissues with high proliferation and the most obvious effect in strongly synthesized DNA cells. Hydroxyurea can stimulate production and increase the concentration of fetal hemoglobin (HB F) and thus the potential to reduce the crescent -shaped red blood cells.
The drug does not cure sickle cell anemia and does not have any role in treating the pain that is progressing, but only the effect of preventing pain.
Hydroxyurea is also used to support the treatment of idiopathic red blood cells, combined with interrupted venous blood extract, because the drug has the effect of inhibiting bone marrow, reducing platelet and red blood cell production.
pharmacokinetics
Hydroxyurea quickly absorbed through the gastrointestinal tract after drinking. Peak concentration in plasma is achieved within 14 hours.
Hydroxyurea is quickly distributed throughout the body, more concentrated in red blood cells and white blood cells. The integral distribution is equal to the water volume in the body. Hydroxyurea passes through blood and brain barriers. The drug is excreted in breast milk.
over 50% of hydroxyurea is metabolized in the liver. A small part of urease, an enzyme of intestinal bacteria, converts into acetohydroxamic acid.
Using hydroxyurea C14 shows about 50% of oral doses that are divested in the liver into CO2 eliminated by respiratory tract and urea excreted through the kidneys. The rest is eliminated through urine in the form of non -metabolic drugs. Hydroxyurea elimination may change in liver failure or kidney failure.
Before taking Hytinon 500mg Korea United Treatment Treatment of chronic leukemia (10 blisters x 10 tablets)
How to use
Hytinon 500mg Used orally. If the patient cannot swallow capsules, may mix the powder in the cyst into a cup of water and drink immediately. Do not inhale or to contact the mucosa or skin. If the drug is poured out, it should be wiped immediately.
Dosage
Adults
Treatment mode may be continuous or interrupted. The continuous mode is more appropriate for chronic leukemia, while interrupt mode is effective on the bone marrow, but gives good response to cervical cancer control.
Use hydroxyurea 7 days before starting treatment simultaneously with radiation. If hydroxyurea is simultaneously used with radiation, often not needed to adjust the dose therapy.
Test time to evaluate hydroxyurea cancer resistance is about 6 weeks. If there is a good clinical response, the treatment may be continued but the patient must be fully monitored and there are no abnormal or serious reactions.
Should stop treatment if the number of white blood cells decreases below 2.5 x 109/l or the number of platelets below 100 x 109/l. In these cases, the number of blood cells should be re -evaluated after three days and continue the treatment regime when the number of cells returns to normal. The recovery of hematopoiesis is usually fast. If recovery quickly does not occur when combining treatment of hydroxyurea and radiation, radiation can be stopped. Anemia, if serious, can also control without having to stop using hydroxyurea.
Serious digestion, such as nausea, vomiting and anorexia due to combined treatment can be controlled by stopping hydroxyurea.
Pain or discomfort due to mucositis at radiation spots is often controlled by measures such as skin anesthetic and painkillers. If the reaction is serious, temporarily stop using hydroxyurea; If the reaction is extremely serious, it may be temporarily postponed.
Continuous treatment
Hydroxyurea 20 - 30mg/kg take one dose daily. Adjust the dose based on the actual weight or the ideal weight of the patient, depending on which weight is lower. Treatment should be monitored by repeating blood formula tests.
Disregard treatment
Hydroxyurea 80mg/kg uses one dose every 3 days. With interruption treatment, less risk of leukopenia, but if leukopenia still occurs, it is advisable to skip one or more doses of hydroxyurea.
Shared hydroxyurea with other bone marrow inhibitors may have to adjust the dose.
Special population
Children
Because the condition rarely occurs in children, there is no treatment for this object.
Elderly
Older patients may be more sensitive to the effects of hydroxyurea, and may need lower doses.
Renal function impairment
Because a part of the drug is excreted by the kidneys, considering reducing hydroxyurea dose in these objects.
What to do when overdose?
Symptoms
Mucosa toxicity has been reported in patients using hydroxyurea at many times higher than the recommended dose. Painful, purple red, edematous palms and soles of the next feet are peeling hands and feet, serious hyperpigmentation has also been reported.
Handling
Instant treatment includes gastric lavage, followed by treatment for the cardiac system if required. After that, it is necessary to monitor the hematopoietic system, if necessary, patients should be blood transfusion.
What to do when forgetting a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.
Side Effects
When using Hytinon 500mg, you may experience unwanted effects (ADR).
Bone marrow inhibitor is the main toxicity of hydroxyurea. Skin vascular toxicity, including ulcers and vascular necrosis, occurred in patients with bone marrow hyperthemis during treatment with hydroxyurea. The risk of poisoning on blood vessels increases in patients who have been or are being treated in interferon.
Skin hyperpigmentation, skin atrophy and nails, skin scales, purple nodules and baldness appear in some patients a few years after long -term treatment with hydroxyurea.
Cases of pancreatitis and toxicity on the liver causing or not causing death, severe peripheral neuritis appeared in HIV -infected patients when taking hydroxyurea in common with antiviral drugs, especially Didanosin in combination with Stavudine. Patients treated with hydroxyurea combined with dahanosin, stavudin and indinavir have an average reduction of CD4 cells about 100/mm³.
The unwanted effect is observed when used in a combination of hydroxyurea and radiation therapy is similar to when using individual hydroxyurea, mainly inhibiting bone marrow (leukopenia and anemia) and stomach irritation. Nearly all patients undergoing the combination of Hydroxyurea and radiation therapy are white blood cells. Platelets ( Very common, ADR> 1/10
Gastrointestinal disorders: pancreatitis*, nausea, vomiting, diarrhea, gastritis, constipation, mucous inflammation, stomach discomfort, indigestion, abdominal pain, black stool. Skin and subcutaneous tissue disorders: skin vasculitis, muscle dermatitis, baldness, skin rash, lumpy, skin peeling, skin atrophy, skin ulcers, erythema, hyperpigmentation, nail changes. Kind and urinary tract disorders: difficulty urinating, increased blood creatinine, hyperemia, hyperuricemia. Common, 1/100 Psychological disorders: illusion, disorientation. Intermediate disorders, chest and respiratory system: pulmonary fibrosis, pulmonary edema, lung infiltration, shortness of breath. Liver disorders: liver toxicity, increased liver enzymes, biliary stasis, hepatitis. Rare, 1/10000 *: Pancreatitis and toxicity on the liver causing or non -fatal and severe peripheral neuritis have been reported in HIV -infected patients using hydroxyurea with antacids, especially Didanosin and Stavudin. Instructions on how to handle ADR When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.
Warnings
Before using the drug you need to read the instructions carefully and refer to the information below.
Contraindicated
Hytinon 500mg drug is contraindicated in the following cases:
Patients with hypersensitivity to hydroxyurea or any ingredients of the drug.
Patients with significant leukopenia (2.5 x 109/l), thrombocytopenia (
Precautions when used
Check the overall condition of blood including evaluation of bone marrow function, as well as liver and kidney function before and during treatment. If the bone marrow function is impaired, do not start treating with hydroxyurea. HAIMOGLOBIN levels should be determined, the total number of white blood cells, the total number of platelets at least once a week during the Hydroxyurea treatment process. If the number of white blood cells decreases below 2.5 x 109/l or the number of platelets below 100 x 109/l, should stop treatment. Check the number after 3 days and continue treatment when values return to normal.
Hydroxyurea can cause bone marrow inhibition, and the first and common manifestation is leukopenia. Thresses and anemia are less likely to occur and rarely occur without previous leukopenia. Bone marrow function impairment often occurs in patients who have been treated with radiation therapy or use of cytotoxic chemotherapy; Be careful when using hydroxyurea in these patients. Bone marrow inhibition often recovers quickly when discontinued.
severe anemia must be treated before starting treatment with hydroxyurea. If anemia occurs during treatment, it is necessary to conduct anemia treatment without stopping treatment with hydroxyurea. Extraordinary red blood cells, huge red blood cell anemia at a limit and often occur when they started treatment with hydroxyurea. The phenotypic change is like malignant anemia, but is not related to the deficiency of vitamin B12 or folic acid. This can hinder diagnosis of folic acid deficiency, which is recommended periodically to measure plasma folic acid levels. Hydroxyurea also slows iron purification in plasma and reduces the fetal iron absorption rate but does not seem to change the existence time of red blood cells.
Patients who have been treated for radiation therapy, may be increased in the erythema after radiation therapy. Hydroxyurea should be carefully used in patients with significant impaired renal function. Hydroxyurea is not used with anti -Retrovirus drugs to treat HIV and may fail or increase the toxicity of treatment (some cases can be fatal) in HIV patients.
In some long -term patients with hydroxyurea for bone marrow hypertrophy disorders, such as red blood cell hypertension, there has been a report on secondary blood cancer. It is unclear whether the effect on this hematopathy is secondary after taking hydroxyurea or related to the patient's hidden disease. Skin cancer has also been reported in patients with long -term hydroxyurea treatment. It is recommended that patients protect the skin from the sun, self -examination of the skin and should be reviewed secondary cancer during regular examination.
Skin vascular toxicity, including ulcers and blood vessel necrosis, occurs in patients with bone marrow hyperetopers during treatment with hydroxyurea. The risk of vascular toxicity increases in patients who used to be treated with interferon. Because of the serious clinical consequences for skin vascular ulcer complications in patients with bone marrow hypertrophy, hydroxyurea should be discontinued when skin vascular ulcer develops, and replaced with other cytotoxic poisoning. The ability to anticipate plasma uric acid should be anticipated, leading to gout development or worse than kidney disease caused by uric acid in patients treated with hydroxyurea, especially when used with other cellular poisoning. Therefore, it is necessary to regularly monitor uric acid levels and maintain the amount of water absorbed during treatment.
vaccine vaccine: Sharing hydroxyurea with vaccines containing live viruses at risk of producing viruses and/or increasing some unwanted effects of the vaccine containing viruses by normal immune mechanism that can be inhibited by hydroxyurea. Vaccine with vaccines live in patients using hydroxyurea can lead to serious infections. The patient's antibodies responding to vaccines may be impaired. Avoid using vaccines during treatment and at least six months after the end of treatment.
The ability to drive and operate machines
hydroxyurea can cause drowsiness. Patients who use drugs should not drive or operate machinery unless the drug does not affect the physical or mental patient.
Pregnancy
drugs that have the ability to synthesize DNA as hydroxyurea may be a strong mutant cause. Doctors should consider carefully before taking this medication for male and female patients who have a child. Hydroxyurea is known to be a teratogenic agent in animals. Therefore, Hydroxyurea should not be used for pregnant women or suspected pregnancy, unless the physician has considered the benefits of taking the drug than the possible dangers.
Breastfeeding period
Hydroxyurea distributed into breast milk. Because of the ability to cause serious side effects of hydroxyurea for babies, they decide to stop breastfeeding or stop taking drugs that consider the importance of the drug for the mother. When necessary, patients should be advised on the use of contraception before and during treatment with hydroxyurea.
Medicinal interaction
Activated bone marrow inhibitors may occur in patients who have or are taking radiation therapy or cytotoxic drugs. Pancreatitis caused or non -fatal had occurred in HIV -infected patients while treating with hydroxyurea and didanosin, coordinated or non -coordinated with Stavudine.
Hepatic toxicity and liver failure lead to deaths after bringing the drug to the market in HIV patients treated with hydroxyurea and other retrovirus inhibitors. Deathly liver events are usually reported in patients with combination treatment of hydroxyurea, didanosin and stavudin. Should avoid using this combination.
Peripheral neuritis, often serious in some cases, has been reported in HIV -infected patients using hydroxyurea in combination with retrovirus anti -Retrovirus drugs, including didanosin, coordinated or not coordinated with stavudin.
Studies show that hydroxyurea is influenced by analytical results for enzymes (urease, uricase, and lactic dehydrogenase) used to quantify urea, uric acid and lactic acid, increasing the results of these tests in patients treated with hydroxyurea.
vaccine
Increased risk of serious or fatal infections when used with live vaccines. It is recommended not to use Vaccine to live in immunodeficiency patients.
Storage
Store at temperatures below 30 ° C, avoiding light.
Other drugs
- BETAHISTINE HYDROCHLORIDE 16MG TABLETS
- IRONORM CAPSULES
- Mysimba
- SMOFKABIVEN PERIPHERAL EMULSION FOR INFUSION
- SEPTRIN 160MG/800MG FORTE TABLETS
- Trimbow
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions